Moreover, CD155 expression did not correlate with PD-L1 expression in tumor cells using the 73–10 assay, but was significantly correlated with PD-L1 expression in tumor cells using the SP142 assay, with 59.0% of patients demonstrating CD155 and/or PD-L1 expression in tumor cells using the 73–10 assay, and 63.3% of patients demonstrating CD155 and/or PD-L1 expression in immune cells using the SP142 assay. Here, PVR is linked to neoplasm.